Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution

Japanese Journal of Ophthalmology

Volumn 58, Issue 2, 2014, Pages 212-217

  Sakata, Rei ^a   Shirato, Shiroaki ^b   Miyata, Kazunori ^c   Aihara, Makoto ^b  

^a Tokyo Metropolitan Institute of Gerontology   (Japan)

^b Yotsuya Shirato Eye Clinic   (Japan)

^c Miyata Eye Hospital   (Japan)

Author keywords

BAK preserved tafluprost; Deepening of the upper eyelid sulcus; Japanese; Prostaglandin analog; Prostaglandin associated periorbitopathy

Indexed keywords

BENZALKONIUM CHLORIDE; TAFLUPROST;

ADULT; ARTICLE; DEEPENING OF THE UPPER EYELID SULCUS; EYELID DISEASE; FEMALE; HUMAN; INCIDENCE; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN ANGLE GLAUCOMA; OPEN STUDY; OPHTHALMOLOGIST; OPTIC NERVE; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SLIT LAMP; UPPER EYELID; VISUAL FIELD;

ANTIHYPERTENSIVE AGENTS; EYELID DISEASES; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; ORBITAL DISEASES; PRESERVATIVES, PHARMACEUTICAL; PROSPECTIVE STUDIES; PROSTAGLANDINS F;

EID: 84896494800     PISSN: 00215155     EISSN: 16132246     Source Type: Journal    
DOI: 10.1007/s10384-013-0299-8     Document Type: Article

References (27)

1. Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008;53(Suppl 1):S69-84.
2. Pantcheva MB, Seibold LK, Awadallah NS, Kahook MY. Tafluprost: a novel prostaglandin analog for treatment of glaucoma. Adv Ther. 2011;28:707-15.
3. Alm A, Grierson I, Shields MB. Side effects associated with prostaglandin analog therapy. Surv Ophthalmol. 2008;53(Suppl 1):S93-105.
4. http://www.aao.org/pdf/Glaucoma-2011-Syllabus.pdf. Accessed 5 July 2013.
5. Peplinski LS, Albiani Smith K. Deepening of lid sulcus from topical bimatoprost therapy. Optom Vis Sci. 2004;81:574-7. (Pubitemid 39095648)
6. Filippopoulos T, Paula JS, Torun N, Hatton MP, Pasquale LR, Grosskreutz CL. Periorbital changes associated with topical bimatoprost. Ophthalmic Plast Reconstr Surg. 2008;24:302-7.
7. Yam JC, Yuen NS, Chan CW. Bilateral deepening of upper lid sulcus from topical bimatoprost therapy. J Ocul Pharmacol Ther. 2009;25:471-2.
8. Tappeiner C, Perren B, Iliev ME, Frueh BE, Goldblum D. Orbital fat atrophy in glaucoma patients treated with topical bimatoprost - can bimatoprost cause enophthalmos? Klin Monbl Augenheilkd. 2008;225:443-5. (Pubitemid 352016479)
9. Yang HK, Park KH, Kim TW, Kim DM. Deepening of eyelid superior sulcus during topical travoprost treatment. Jpn J Ophthalmol. 2009;53:176-9.
10. Aihara M, Shirato S, Sakata R. Incidence of deepening of the upper eyelid sulcus after switching from latanoprost to bimatoprost. Jpn J Ophthalmol. 2011;55:600-4.
11. Maruyama K, Shirato S, Tsuchisaka A. Incidence of deepening of the upper eyelid sulcus after topical use of travoprost ophthalmic solution in Japanese. J Glaucoma. 2012. doi:10.2147/OPTH.S47783.
12. Ung T, Currie ZI. Periocular changes following long-term administration of latanoprost 0.005%. Ophthalmic Plast Reconstr Surg. 2011. doi:10.1097/IOP.0b013e31821d86a5.
13. Inoue K, Shiokawa M, Wakakura M, Tomita G. Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs. J Glaucoma. 2013;22:626-31.
14. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, et al. New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003;26:1691-5. (Pubitemid 39663527)
15. Uusitalo H, Pillunat LE, Ropo A. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88:12-9.
16. Schnober D, Hofmann G, Maier H, Scherzer ML, Ogundele AB, Jasek MC. Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2010;4:1459-63.
17. Nakano T, Yoshikawa K, Kimura T, Suzumura H, Nanno M, Noro T. Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less. Jpn J Ophthalmol. 2011;55:605-13.
18. Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28:575-85.
19. Chabi A, Varma R, Tsai JC, Lupinacci R, Pigeon J, Baranak C, et al. Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2012;153:1187-96.
20. Chaudhary O, Adelman RA, Shields MB. Predicting response to glaucoma therapy in one eye based on response in the fellow eye: the monocular trial. Arch Ophthalmol. 2008;126:1216-20.
21. Dayanir V, Cakmak H, Berkit I. The one-eye trial and fellow eye response to prostaglandin analogues. Clin Experiment Ophthalmol. 2008;36:136-41. (Pubitemid 351445146)
22. Sakata R, Shirato S, Miyata K, Aihara M. Recovery from deepening of the upper eyelid sulcus after switching from bimatoprost to latanoprost. Jpn J Ophthalmol. 2013;57:179-84.
23. Park J, Cho HK, Moon JI. Changes to upper eyelid orbital fat from use of topical bimatoprost, travoprost, and latanoprost. Jpn J Ophthalmol. 2011;55:22-7.
24. Casimir DA, Miller CW, Ntambi JM. Preadipocyte differentiation blocked by prostaglandin stimulation of prostanoid FP2 receptor in murine 3T3-L1 cells. Differentiation. 1996;60:203-10. (Pubitemid 26265757)
25. Miller CW, Casimir DA, Ntambi JM. The mechanism of inhibition of 3T3-L1 preadipocyte differentiation by prostaglandin F2alpha. Endocrinology. 1996;137:5641-50.
26. Serrero G, Lepak NM. Prostaglandin F2alpha receptor (FP receptor) agonists are potent adipose differentiation inhibitors for primary culture of adipocyte precursors in defined medium. Biochem Biophys Res Commun. 1997;233:200-2. (Pubitemid 27215935)
27. Strong P, Coleman RA, Humphrey PP. Prostanoid-induced inhibition of lipolysis in rat isolated adipocytes: probable involvement of EP3 receptors. Prostaglandins. 1992;43:559-66.